Hagit Bergman1, Tara Walton2, Ryan Del Bel3, Jack T Seki4, Ava Rafii5, Wei Xu3, Gideon Koren5, Neil Shear6, Monika K Krzyzanowska7, Doris Howell2, Geoffrey Liu7. 1. Department of Clinical Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. Electronic address: hbergman@uhnres.utoronto.ca. 2. Ontario Patient-Reported Outcomes of Symptoms and Toxicity, Princess Margaret Cancer Center and Ontario Cancer Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada. 3. Department of Biostatistics, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada. 4. Department of Pharmacy, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada. 5. Department of Clinical Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. 6. Department of Dermatology, Sunnybrook Hospital, University of Toronto, Toronto, Ontario, Canada. 7. Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Ontario Patient-Reported Outcomes of Symptoms and Toxicity, Princess Margaret Cancer Center and Ontario Cancer Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada; Medical Oncology and Hematology Division, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Dermatologic toxicities from targeted agents such as panitumumab can interfere with cancer treatment. OBJECTIVE: We sought to evaluate the rash assessment and management in a consecutive patient cohort who received panitumumab for colorectal cancer treatment. METHODS: This was a retrospective chart review. RESULTS: Skin toxicity, consisting of papulopustular rash, was experienced by 32 of 34 patients. The majority (85%) developed the rash by the end of the second infusion cycle. Patients presented with a mild (41%), moderate (38%), and severe (21%) rash, and progressed to an extensive rash without appropriate treatment. A grading system was used for 65% of patients to document severity. LIMITATIONS: Small sample size limited power in analysis. Rash severity had to be inferred based on rash description and management in 11 of the patients. CONCLUSION: Dermatologic toxicities related to panitumumab are common; however, the way they are reported and managed varies among physicians. To prevent progression, toxicities must be assessed and treated early and aggressively, according to severity grading. Dermatologists could aid oncologists in choosing the best management strategies.
BACKGROUND: Dermatologic toxicities from targeted agents such as panitumumab can interfere with cancer treatment. OBJECTIVE: We sought to evaluate the rash assessment and management in a consecutive patient cohort who received panitumumab for colorectal cancer treatment. METHODS: This was a retrospective chart review. RESULTS:Skin toxicity, consisting of papulopustular rash, was experienced by 32 of 34 patients. The majority (85%) developed the rash by the end of the second infusion cycle. Patients presented with a mild (41%), moderate (38%), and severe (21%) rash, and progressed to an extensive rash without appropriate treatment. A grading system was used for 65% of patients to document severity. LIMITATIONS: Small sample size limited power in analysis. Rash severity had to be inferred based on rash description and management in 11 of the patients. CONCLUSION: Dermatologic toxicities related to panitumumab are common; however, the way they are reported and managed varies among physicians. To prevent progression, toxicities must be assessed and treated early and aggressively, according to severity grading. Dermatologists could aid oncologists in choosing the best management strategies.
Authors: L Peuvrel; J Cassecuel; C Bernier; G Quéreux; M Saint-Jean; M Le Moigne; C Frénard; A Khammari; B Dréno Journal: Support Care Cancer Date: 2018-03-12 Impact factor: 3.603
Authors: Mario E Lacouture; Milan Anadkat; Aminah Jatoi; Tamer Garawin; Chet Bohac; Edith Mitchell Journal: Clin Colorectal Cancer Date: 2017-12-13 Impact factor: 4.481
Authors: Matthias F Froelich; Sebastian Stintzing; Jörg Kumbrink; Thomas G P Grünewald; Ulrich Mansmann; Volker Heinemann; Thomas Kirchner; Andreas Jung Journal: Oncotarget Date: 2018-07-13